Related Experiment Video

Updated: Aug 1, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

H Quentmeier1, R A F MacLeod, M Zaborski

  • 1DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany. hqu@dsmz.de

Leukemia
|January 13, 2006
PubMed

Insights

The Janus kinase 2 (JAK2 V617F) mutation, common in myeloproliferative disorders, was found in five acute myeloid leukemia cell lines. These cell lines offer new tools for studying JAK2 V617F in myeloid malignancies.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The Janus kinase 2 (JAK2) V617F mutation is a key driver in chronic myeloproliferative disorders (MPD).
  • Its presence and role in acute myeloid leukemia (AML) require further investigation.
  • Understanding JAK2 V617F in AML can reveal novel therapeutic targets.

Purpose of the Study:

  • To screen AML cell lines for the JAK2 V617F mutation.
  • To characterize the genetic and cytogenetic landscape of JAK2-mutated AML cell lines.
  • To evaluate the utility of these cell lines for studying JAK2 V617F pathobiology.

Main Methods:

  • Screening of 79 AML cell lines for JAK2 V617F using molecular assays.
  • Microsatellite analysis and fluorescence in situ hybridization (FISH) for loss of heterozygosity (LOH) and cytogenetic abnormalities.
  • Assessment of JAK2 inhibition sensitivity in JAK2-mutated versus wild-type cell lines.

Main Results:

  • Five AML cell lines (HEL, MB-02, MUTZ-8, SET-2, UKE-1) tested positive for JAK2 V617F, with four having histories of MPD/myelodysplastic syndromes (MDS).
  • Loss of heterozygosity (LOH) at the JAK2 locus was observed, with evidence of chromosome deletion and JAK2 amplification.
  • JAK2-mutated cell lines exhibited increased sensitivity to JAK2 inhibition compared to JAK2 wild-type lines.

Conclusions:

  • JAK2 V617F is present in a subset of AML cell lines, often associated with MPD/MDS history and specific cytogenetic aberrations.
  • Novel mechanisms involving chromosome deletion and amplification contribute to JAK2 LOH.
  • These JAK2 V617F-positive AML cell lines are valuable tools for dissecting the role of this mutation in myeloid malignancies and for testing targeted therapies.

More Related Videos

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Cell Lines01:16

Cell Lines

A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...